&
The first clinical study of a synthetic peptide-based vaccine against the Epstein-Barr virus (EBV) is now underway. Researchers are hopeful that the vaccine, which contains a cytotoxic T-lymphocyte (CTL) epitope, may protect against EBV immunopathology. Inpharma spoke to Dr Andreas Suhrbier, from the Queensland Institute of Medical Research, Brisbane, Australia, about the current phase I trial and the potential applications for an EBV vaccine in protecting against infectious mononucleosis (glandular fever) and the development of post-transplant lymphoproliferative disease (PTLD).
Rights and permissions
About this article
Cite this article
Barnes, J. Peptide-based EBV vaccine in phase I trial. Inpharma Wkly. 985, 11–12 (1995). https://doi.org/10.2165/00128413-199509850-00025
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-199509850-00025